Chengdu Bright Eye Hospital Past Earnings Performance
Past criteria checks 2/6
Chengdu Bright Eye Hospital has been growing earnings at an average annual rate of 29%, while the Healthcare industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 43.9% per year. Chengdu Bright Eye Hospital's return on equity is 5.7%, and it has net margins of 4.5%.
Key information
29.0%
Earnings growth rate
20.0%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 43.9% |
| Return on equity | 5.7% |
| Net Margin | 4.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Chengdu Bright Eye Hospital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,744 | 122 | 953 | 11 |
| 31 Dec 23 | 2,718 | 268 | 917 | 11 |
| 30 Sep 23 | 2,459 | 244 | 836 | 9 |
| 30 Jun 23 | 2,214 | 204 | 791 | 9 |
| 31 Mar 23 | 1,907 | 146 | 725 | 9 |
| 01 Jan 23 | 1,726 | 21 | 696 | 7 |
| 30 Sep 22 | 1,785 | 70 | 679 | 4 |
| 30 Jun 22 | 1,753 | 80 | 659 | 3 |
| 31 Mar 22 | 1,755 | 99 | 647 | 0 |
| 01 Jan 22 | 1,710 | 94 | 627 | 0 |
| 31 Dec 20 | 1,362 | 109 | 425 | 0 |
| 31 Dec 19 | 1,193 | 49 | 410 | 0 |
| 31 Dec 18 | 1,016 | 31 | 358 | 0 |
| 31 Dec 17 | 806 | -13 | 298 | 0 |
Quality Earnings: 301239 has high quality earnings.
Growing Profit Margin: 301239's current net profit margins (4.5%) are lower than last year (7.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301239's earnings have grown significantly by 29% per year over the past 5 years.
Accelerating Growth: 301239's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301239 had negative earnings growth (-15.9%) over the past year, making it difficult to compare to the Healthcare industry average (-1%).
Return on Equity
High ROE: 301239's Return on Equity (5.7%) is considered low.